Ligand Pharmaceuticals (LGND) Competitors

Repligen (NASDAQ:RGEN) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.

Does the media refer more to RGEN or LGND?

In the previous week, Repligen had 6 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 12 mentions for Repligen and 6 mentions for Ligand Pharmaceuticals. Repligen's average media sentiment score of 1.51 beat Ligand Pharmaceuticals' score of 1.13 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ligand Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate RGEN or LGND?

Repligen presently has a consensus target price of $178.64, indicating a potential upside of 59.58%. Ligand Pharmaceuticals has a consensus target price of $147.00, indicating a potential upside of 47.63%. Given Repligen's higher possible upside, equities analysts plainly believe Repligen is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor RGEN or LGND?

Ligand Pharmaceuticals received 138 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 70.59% of users gave Ligand Pharmaceuticals an outperform vote while only 67.43% of users gave Repligen an outperform vote.

Company	Underperform	Outperform
Repligen	Outperform Votes 414 67.43%	Underperform Votes 200 32.57%
Ligand Pharmaceuticals	Outperform Votes 552 70.59%	Underperform Votes 230 29.41%

Do insiders & institutionals have more ownership in RGEN or LGND?

97.6% of Repligen shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 1.2% of Repligen shares are owned by company insiders. Comparatively, 5.9% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has higher earnings & valuation, RGEN or LGND?

Ligand Pharmaceuticals has lower revenue, but higher earnings than Repligen. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$634.44M	9.91	$35.60M	-$0.51	-219.49
Ligand Pharmaceuticals	$167.13M	11.47	$52.15M	-$0.16	-622.31

Which has more risk & volatility, RGEN or LGND?

Repligen has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Is RGEN or LGND more profitable?

Ligand Pharmaceuticals has a net margin of 29.68% compared to Repligen's net margin of -4.64%. Ligand Pharmaceuticals' return on equity of 4.95% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	-4.64%	4.21%	2.94%
Ligand Pharmaceuticals	29.68%	4.95%	4.39%

Summary

Ligand Pharmaceuticals beats Repligen on 12 of the 18 factors compared between the two stocks.